Compugen Ltd.(Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, todayannounced that management will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference.
The fireside chat will be available on demand on the Investor Relations section of Compugen's websiteat www.cgen.comfrom Friday, September 5, 2025, 7:00 AM ETfor 90 days.
AboutCompugen
Compugenis a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902,a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies.GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stageimmuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugenis headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel AvivStock Exchange under the ticker symbol CGEN.
Company contact:Yvonne Naughton, Ph.D.Vice President, Head of Investor Relations and Corporate CommunicationsEmail:ir@cgen.comTel: +1(628)241-0071
https://c212.net/c/img/favicon.png?sn=LN61048&sd=2025-08-28
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302540915.html
SOURCE Compugen Ltd.
https://rt.newswire.ca/rt.gif?NewsItemId=LN61048&Transmission_Id=202508280700PR_NEWS_USPR_____LN61048&DateId=20250828